In addition to teaching you advanced strategies and sustainable systems for GLP-1s, we will also give you the exact Million Dollar Blueprint to build a 7 figure clinic, in just 12 months
A: The same cautions apply to Mounjaro (tirzepatide) and Wegovy (semaglutide)
Risk factors that may prompt additional consideration include: Active gastrointestinal symptoms (nausea, vomiting, abdominal pain) Recent dose increases or being in the dose-escalation phase Higher doses of semaglutide Known gastroparesis or other conditions affecting gastric emptying Obesity with GERD or hiatal hernia Based on the 2024 multi-society guidance, most patients can continue GLP-1 receptor agonists before elective procedures with appropriate risk assessment and mitigation strategies, rather than automatic postponement
However, there are certain patients for whom Wellbutrin should be avoided, including those with: A diagnosis of an eating disorder, like anorexia A seizure disorder Taking monoamine oxidase inhibitors (MAOIs) A known allergic reaction Labeling for Wellbutrin, like most antidepressants, was updated in 2005 to add a warning that it may cause rare cases of depression and comes with a risk of suicidal thoughts, especially in young adults
Studies have explored its function as a triple agonist, interacting with glucagon-like peptide, glucose-dependent insulinotropic polypeptide, and glucagon pathways within metabolic communication research between the gut, brain, and endocrine system